Contact Us
Drug Search Results
More Filters [+]

Conestat alfa

Alternative Names: conestat alfa, rhc1inh
Latest Update: 2024-11-07
Latest Update Note: Clinical Trial Update

Product Description

Pharming Technologies B.V. is developing Conestat alfa as a treatment for SARS-CoV-2. (Sourced from: https://clinicaltrials.gov/study/NCT04414631?tab=history&a=6)

Mechanisms of Action: C1 Inhibitor

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Colombia | Croatia | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Pharming Technologies B.V.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Conestat alfa

Countries in Clinic: Switzerland

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Acute Kidney Injury|Ischemic Stroke

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
PAIR-TAVI

P2

Recruiting

Acute Kidney Injury|Ischemic Stroke

2025-03-01

Recent News Events

Date

Type

Title

01/22/2024

PubMed

 Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks.

10/27/2023

PubMed

 Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial.

11/08/2022

News Article

 Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment

04/01/2022

News Article

 Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

04/01/2022

News Article

 Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

07/26/2021

News Article

 Acute Kidney Injury (AKI) Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

01/01/2006

PubMed

 C1 Esterase Inhibitor.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions